Navigation Links
University of Western Ontario researchers investigate stress and breast cancer
Date:9/20/2011

It's a common belief that there's a link between chronic stress and an increased risk of cancer. In new research published online by the International Journal of Cancer, scientists at The University of Western Ontario have taken a step toward confirming that belief.

Research led by Dwayne Jackson of the Departments of Medical biophysics and Biomedical Engineering has identified a particular neurotransmitter released in response to stress, that stimulates both cancer cell growth and migration in breast cancer.

Working with Ph.D candidate Philip Medeiros, Jackson looked at a branch of the nervous system called the sympathetic nervous system, and how it "talks" to cells in various organs throughout the body. When the sympathetic nervous system is activated, like it is during stress, it communicates with receptors on cells through the release of neurotransmitters called norepinephrine and neuropeptide Y or NPY. This is a normal response that prepares the body for "fight or flight".

"We have all heard anecdotally that stress causes cancer. Our lab is particularly interested in how chronic stress may cause increases in the release of NPY and whether that may contribute to the progression of breast cancer," explains Jackson, an Assistant Professor at Western's Schulich School of Medicine & Dentistry. "It has been shown that women with a familial history of breast cancer exhibit greater physiological stress responses to normal everyday stressors. Since there is a very dense supply of sympathetic nerves in the female breast, it would be reasonable to suspect that NPY may be released in greater amounts in the breasts of those at risk for breast cancer. Thus, we postulated if cancer cells are present and they respond to NPY, then this neuropeptide and its receptors would form a functional link between stress and breast cancer progression."

"Once we had established that breast cancer cells express the receptors for NPY, then we went through a set of experiments that looked at the functional consequences of activating them. We found NPY greatly accelerates cell growth as well as cell migration and these are two important steps in primary tumour growth, as well as in metastasis," concludes Medeiros.


'/>"/>
Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert

Related biology technology :

1. SanBio Announces Site Opening of Phase 1/2a Clinical Trial of Novel Cell Therapy in Stable Stroke Patients at University of Pittsburgh Medical Center
2. HUYA Bioscience International Forms Alliance With Zhejiang Chinese Medical University Life Science College
3. Swedish University Hospital Improves Monitoring of Treatment Efficacy in Multiple Sclerosis With Synthetic MRI Innovation
4. University of Houston receives NSF grant for high school teachers program
5. New nanoscale parameter by Aalto University resolves dilemmas on silicon property
6. University of Muenster Bridges 1st Patient to Transplant with SynCardias Total Artificial Heart
7. Elsevier and the National University of Singapore Announce Winners of 24-Hour Hackathon
8. The Human Brain is Sensitive to Light, Breakthrough Findings From Valkee and the University of Oulu
9. CEM President and CEO Delivers Commencement Address at the University of Texas at Austin Chemistry and Biochemistry Department Graduation
10. Computerized system to prevent SIDS developed by Ben-Gurion University students
11. University of Dayton Study Overturns 250-Year-Old Belief About Effects of Age, Repeated Injury on Tissue Regeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):